A leading pharmaceutical company has identified CAR-T Immunotherapy as a focus area, aiming to invest and drive innovation in this sector.

​

• KIIC conducted industry research and scouting and designed a customized delegation for their members' senior management and investment teams. By connecting them with key players in the ecosystem, the startup emerged as a highly suitable solution, with a strong team and an impressive list of investors.

 

The business opportunity

 

For KIIC member: expand knowledge and potentially broaden offerings in the field of CAR-T Immunotherapy.

 

For the startup: leverage the member's expertise and geographical distribution through potential future partnerships such as licensing or strategic cooperation.

 

The deal info & framework​
 

• Despite the challenges posed by Covid-19, the entire process, including scouting, introduction, startup due diligence, and legal framework establishment, was successfully conducted remotely.
   

• The investment was made alongside tier1 global VCs expanding the network and investor relations of the KIIC member for future co-investment opportunities